Home
United BioPharma

United BioPharma Market Share Analysis for July 2026

聯合生物製藥(簡稱聯生藥,ubp)於2013年由母公司聯亞生技開發(股)公司之抗體藥品事業切割成立。有別於一般創新公司，聯生藥傳承具有30年歷史的ubi集團科學技術，以有醫學的秘密武器之稱的免疫學深厚知識能量，專注於自主研發與製造可有效解決現有治療方案缺陷的創新高品質抗體藥物，確實提升病患健康與生活質量，追求實現價值極大化。

Health > Biotechnology and Pharmaceuticals

Domainunitedbiopharma.com

Year Founded2013

Employees51 - 200

Annual Revenue$15M - $25M

United BioPharma

United BioPharma (including company regionals)

unitedbiopharma.com

See more website traffic and engagement information

United BioPharma Revenue up to July 2026 is 15M - 25M

revenue generated by United BioPharma top domains

United BioPharma top domains revenue over 3 years

Revenue for United BioPharma top domains

unitedbiopharma.com15M - 25M

See more with Sales Intelligence

Total visits to United BioPharma's top domains

Understand United BioPharma market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in United BioPharma's top domains

Analyze United BioPharma engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on United BioPharma's top domains

See how United BioPharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

United BioPharma top competitors by domain

Top similar sites in July 2026, ranked by their affinity

clinicaltrials.govCompany NameClinicalTrials.govEmployees201 - 500HQUnited States, North Carolina, DurhamAnnual revenue$15M - $25MTotal visits3.2MHealth > Health - Other

Top technologies used by United BioPharma

These are the website technologies, by industry, used by United BioPharma top domains

Social (3)

Facebook Social Plugins

Email Services (2)

G Suite

Mobile (2)

Meta Viewport

Advertising (1)

DoubleClick

More Technologies

6

See all

News & Signals from United BioPharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsUnitedbiopharma is developing UB-621.And United BioPharma is developing UB-621 as a first-in-class anti-gD monoclonal antibody candidate with demonstrated viral suppression of transmission and recurrence of HSV-1 and HSV-2.

NewsUnitedbiopharma launches UB-421.United BioPharma (UBP) today announced that its monoclonal antibody product, UB-421, is able to suppress HIV for at least four months in patients who previously paused their antiretroviral therapy (ART) regimen.